Optimizing outcomes and efficiency: iCAD’s world-class solutions for the early detection and treatment of cancer

Hosted by iCAD Inc. (NASDAQ: ICAD)

Watch iCAD’s 2nd annual virtual investor webinar, featuring leading clinical and administrative experts who will share unique perspectives on iCAD’s innovative cancer detection and treatment technologies. Learn how iCAD’s portfolio of deep-learning AI breast health solutions and the Xoft System offer practical solutions that are expertly engineered to enhance clinical workflow, optimize operational efficiency, and improve outcomes for patients.

Featured Experts:

• Angela Fried, MD, Director of Breast Imaging, SimonMed Imaging
• Sally Grady, Director, Kettering Breast Evaluation Centers, Kettering Health
• Meghan Musser, DO, Radiologist, Kettering Health
• Matt Dewey, Chief Information Officer, Wake Radiology
• Sidney P. Smith, MD, Dermatologist, Chief Executive Officer, Georgia Skin & Cancer Clinic

​

Pandemic Recovery: How New Technology Can Support Clinicians and Patients in the Aftermath of COVID-19

As we shift from the peak of the pandemic to recovery mode, clinicians are in need of new solutions to navigate today’s challenges. During this virtual event, leading experts from the breast care community shared insights about new innovations in imaging and risk-assessment that may help the clinical community address emerging pandemic challenges, and best practices for how facilities can recuperate from the impact of COVID-19. Learn how the latest technology can help clinicians optimize workflow and patient care during the COVID-19 recovery period and beyond.

​

iCAD Technology Innovation Day – Expanded ProFound AI Portfolio

Featuring presentations by Key Opinion Leaders Per Hall, MD, PhD (Karolinska Institutet), Axel Gräwingholt, MD (Radiologie am Theater), Joshua A. Nepute, MD (Indiana University Health-Arnett), and Emily F. Conant, MD (University of Pennsylvania Perelman School of Medicine) who will discuss the current landscape for digital breast tomosynthesis (DBT) and the potential for iCAD's recently introduced ProFound AI Risk, the first and only commercially available clinical decision support tool that provides an accurate two-year breast cancer risk estimation based solely on a screening mammogram.

​

iCAD Technology Innovation Day – Expanded Therapy Portfolio

Featuring presentations by Key Opinion Leaders (KOLs) Janie Grumley, MD, FACS (John Wayne Cancer Center), Té Vuong, MD, FRCP (McGill University & Jewish General Hospital), and Santosh Kesari, MD, PhD (John Wayne Cancer Center), who discuss the current treatment landscape and unmet medical need in treating patients with cancers such as breast, rectal, and glioblastoma multiforme. Also highlighted will be recently presented positive clinical data for Xoft® Brain IORT as viable treatment option for glioblastoma multiforme.

​